Skip to content
Screener

CytomX Therapeutics CTMX Q1 2025 earnings

Reported May 12, 2025 · Before market open

Revenue$50.9MBeat by $15.5M
EPS$0.27Beat by $0.15
Revenue estimate$35.4M
EPS estimate$0.12

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$10.4M
EPS estimate-$0.09

Financials

Q1 2025

Income statement

See full
Revenue$50.9M+22.8%
Operating income$22.6M+94.1%
Net income$23.5M+70.6%
EPS (diluted)$0.27+58.8%

Balance sheet

See full
Cash & equivalents$47.6M+31.6%
Total debt$8.1M-36.7%
Total equity$25.0M+179%
Total assets$98.5M-46.7%

Cash flow

See full
Operating cash flow-$21.0M+19.2%
CapEx$119.0K+3.5%
Free cash flow-$21.2M+19.1%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$50.93M-65.5%
Enterprise value$11.47M-90.8%
P/E1.2×—
P/S0.3×-0.9×

Profitability

See full
Operating margin24.4%+15.3pp
Net margin28.2%—
FCF margin-55.3%-12.3pp

Returns & leverage

See full
Debt / equity0.3×—
Current ratio1.7×+0.6×

FAQ

When did CytomX Therapeutics report Q1 2025 earnings?
CytomX Therapeutics (CTMX) reported Q1 2025 earnings on May 12, 2025 before market open.
What were CytomX Therapeutics's Q1 2025 revenue and EPS?
CytomX Therapeutics reported revenue of $50.9M and eps of $0.27 for Q1 2025.
Did CytomX Therapeutics beat estimates in Q1 2025?
Revenue beat the consensus estimate of $35.4M by $15.5M. EPS beat the consensus estimate of $0.12 by $0.15.
How did CytomX Therapeutics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 22.8% from $41.5M a year earlier and eps grew 58.8% from $0.17.
Where can I find CytomX Therapeutics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-117245) and the 10-Q periodic report (0000950170-25-068511) directly on SEC EDGAR. The filing index links above go to sec.gov.